利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1733 条记录 (耗时 0.065 秒)

    Anti-RANTES Antibodies
    91.
    发明申请
    Anti-RANTES Antibodies 审中-公开
    抗RANTES抗体

    公开(公告)号：US20150079099A1

    公开(公告)日：2015-03-19

    申请号：US14217944

    申请日：2014-03-18

    申请人： NOVLMMUNE S.A.

    发明人： Nicolas Fischer ,  Marie Kosco-Vilbois ,  François Mach

    IPC分类号： C07K16/24

    CPC分类号： C07K16/24 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/30 ,  C07K2317/33 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00

    摘要： The invention relates to fully human monoclonal antibodies, and fragments thereof, that bind to the chemokine Regulated upon Activation, Normal T-cell Expressed, and Secreted (RANTES, CCL5), thereby modulating the interaction between RANTES and one of more of its receptors, such as, e.g., CCR1, CCR3, CCR4 and CCR5, and/or modulating the biological activities of RANTES. The invention also relates to the use of these or any anti-RANTES antibodies in the prevention or treatment of immune-related disorders and in the amelioration of one or more symptoms associated with an immune-related disorder.

    摘要翻译： 本发明涉及完全人单克隆抗体及其片段，其结合活化时调节的趋化因子，表达正常T细胞和分泌型（RANTES，CCL5），从而调节RANTES与其多个受体之一的相互作用， 例如CCR1，CCR3，CCR4和CCR5，和/或调节RANTES的生物学活性。 本发明还涉及这些或任何抗RANTES抗体在预防或治疗免疫相关疾病以及改善与免疫相关病症相关的一种或多种症状中的用途。

    Antagonistic human light-specific human monoclonal antibodies
    92.
    发明授权
    Antagonistic human light-specific human monoclonal antibodies 有权
    拮抗人类光特异性人单克隆抗体

    公开(公告)号：US08974787B2

    公开(公告)日：2015-03-10

    申请号：US13889608

    申请日：2013-05-08

    申请人： Kyowa Hakko Kirin Co., Limited ,  La Jolla Institute for Allergy and Immunology

    发明人： Steven W. Granger ,  Shinichiro Kato ,  Carl F. Ware

    IPC分类号： A61K39/00 ,  C07K16/24 ,  C07K16/28

    CPC分类号： C07K16/24 ,  A61K2039/505 ,  C07K16/2875 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76

    摘要： Provided herein are antibodies that immunospecifically bind to an hLIGHT polypeptide; isolated nucleic acids encoding the antibodies; vectors and host cells comprising nucleic acids encoding the antibodies; methods of making the antibodies; and a method of treating a hLIGHT-mediated disease in a subject comprising administering to the subject the antibodies. In preferred embodiments, the anti-hLIGHT antibodies provided herein will ameliorate, neutralize or otherwise inhibit hLIGHT biological activity in vivo (e.g., the hLIGHT-mediated production or secretion of CCL20, IL-8 or RANTES from a cell expressing a hLIGHT receptor). Also provided herein is a method for the detection of hLIGHT in a sample as well as a method for ameliorating, neutralizing or otherwise inhibiting hLIGHT activity, e.g., in a human subject suffering from a disorder in which hLIGHT activity is detrimental.

    摘要翻译： 本文提供了免疫特异性结合于hLIGHT多肽的抗体; 编码抗体的分离的核酸; 载体和宿主细胞，其包含编码抗体的核酸; 制备抗体的方法; 以及治疗受试者中的hLIGHT介导的疾病的方法，包括向受试者施用抗体。 在优选的实施方案中，本文提供的抗hLIGHT抗体将改善，中和或抑制体内的hLIGHT生物活性（例如，hLIGHT介导的来自表达hLIGHT受体的细胞的CCL20，IL-8或RANTES的产生或分泌）。 本文还提供了用于检测样品中的hLIGHT的方法以及用于改善，中和或抑制hLIGHT活性的方法，例如在患有hLIGHT活性有害的病症的人类受试者中。

    ANTI MIF ANTIBODIES
    95.
    发明申请
    ANTI MIF ANTIBODIES 审中-公开
    抗MIF抗体

    公开(公告)号：US20150023978A1

    公开(公告)日：2015-01-22

    申请号：US14157967

    申请日：2014-01-17

    申请人： Baxter International Inc. ,  Dyax Corp. ,  Baxter Healthcare SA

    发明人： Randolf Kerschbaumer ,  Friedrich Scheiflinger ,  Manfred Rieger ,  Michael Thiele ,  Geert C. Mudde ,  Juergen Muellberg ,  Rene Hoet

    IPC分类号： C07K16/24

    CPC分类号： C07K16/24 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

    摘要： The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions.

    摘要翻译： 本发明涉及特异性结合巨噬细胞迁移抑制因子（MIF）的C端或中心区域的单克隆抗体及其抗原结合部分。 这些抗MIF抗体及其抗原结合部分进一步抑制人MIF生物学功能。 本发明还涉及衍生自抗MIF抗体的分离的重链和轻链免疫球蛋白和编码这种免疫球蛋白的核酸分子。 本发明还涉及鉴定抗MIF抗体的方法，包含这些抗体的药物组合物和使用这些抗体和组合物用于治疗MIF相关病症的方法。

    Method of Treatment and Bioassay Involving Macrophage Migration Inhibitory Factor (MIF) as Cardiac-Derived Myocardial Depressant Factor
    96.
    发明申请
    Method of Treatment and Bioassay Involving Macrophage Migration Inhibitory Factor (MIF) as Cardiac-Derived Myocardial Depressant Factor 审中-公开
    将巨噬细胞迁移抑制因子（MIF）作为心源性心肌抑制因子的治疗和生物测定方法

    公开(公告)号：US20150017179A1

    公开(公告)日：2015-01-15

    申请号：US14281870

    申请日：2014-05-19

    申请人： Baxter International S.A. ,  Baxter Healthcare S.A. ,  Board of Regents, The University of Texas System

    发明人： Brett P. GIROIR ,  Monte S. WILLIS ,  Vidal F. DE LA CRUZ, JR. ,  Thais M. SIELECKI-DZURDZ

    IPC分类号： C07K16/28 ,  C07K16/24

    CPC分类号： C07K16/2878 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/24 ,  C07K16/2833 ,  C07K2317/76

    摘要： One embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-MIF antibody; and at least one pharmaceutically acceptable carrier. Another embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount at least one anti-CD74 antibody; and at least one pharmaceutically acceptable carrier. Another embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-TNFR antibody; a therapeutically effective amount of at least one anti-MIF antibody; and at least one pharmaceutically acceptable carrier. Other embodiments of the present invention relate to methods of treating or preventing cardiac dysfunction, cardiodepression, burn injury-associated cardiac dysfunction, improving cardiac function in a subject following acute myocardial infarction, and identifying an MIF inhibitor.

    摘要翻译： 本发明的一个实施方案涉及药物组合物，其包含治疗有效量的至少一种抗MIF抗体; 和至少一种药学上可接受的载体。 本发明的另一个实施方案涉及药物组合物，其包含治疗有效量的至少一种抗CD74抗体; 和至少一种药学上可接受的载体。 本发明的另一个实施方案涉及药物组合物，其包含治疗有效量的至少一种抗TNFR抗体; 治疗有效量的至少一种抗MIF抗体; 和至少一种药学上可接受的载体。 本发明的其它实施方案涉及治疗或预防心脏功能障碍，心脏抑制，烧伤相关心脏功能障碍，改善急性心肌梗死后受试者心脏功能以及鉴定MIF抑制剂的方法。

    MYONECTIN (CTRP15), COMPOSITIONS COMPRISING SAME, AND METHODS OF USE
    100.
    发明申请
    MYONECTIN (CTRP15), COMPOSITIONS COMPRISING SAME, AND METHODS OF USE 有权
    MYONECTIN（CTRP15），包含其的组合物和使用方法

    公开(公告)号：US20140371142A1

    公开(公告)日：2014-12-18

    申请号：US14373685

    申请日：2013-01-24

    申请人： THE JOHNS HOPKINS UNIVERSITY

    发明人： Guang William Wong ,  Marcus Michael Seldin

    IPC分类号： C07K14/52 ,  C07K16/24

    CPC分类号： A61K38/19 ,  A61K38/00 ,  A61K38/1709 ,  C07K14/47 ,  C07K14/52 ,  C07K14/775 ,  C07K16/24 ,  C07K2317/76

    摘要： Disclosed is the novel myokine known as myonectin (CTRP15), an isolated nucleic acid encoding the myonectin (CTRP15) gene, and the amino acid sequence encoding the myonectin (CTRP15) protein. Methods of isolation of the nucleic acid, protein, polypeptides and methods of making antibodies to the myonectin (CTRP15) protein are provided. The use of myonectin (CTRP15) in the modulation of lipid and/or glucose metabolism, suppressing the expression of autophagy genes, inhibiting LC3 lipidation and autophagosome-dependent p62 degradation, and activating the Akt/mTOR pathway is also provided.

    摘要翻译： 公开了称为肌节蛋白（CTRL15），编码肌节蛋白（CTRL15）基因的分离的核酸和编码肌节蛋白（CTRL15）蛋白质的氨基酸序列的新型肌节蛋白。 提供分离核酸，蛋白质，多肽的方法和制备抗肌球蛋白（CTRL15）蛋白质的方法。 还提供了使用肌球蛋白（CTRP15）调节脂质和/或葡萄糖代谢，抑制自噬基因的表达，抑制LC3脂化和自噬体依赖性p62降解以及激活Akt / mTOR途径。